Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 4
2001 1
2002 2
2003 2
2004 4
2006 1
2007 2
2008 1
2009 2
2010 2
2011 5
2012 5
2013 4
2014 3
2015 1
2016 7
2017 7
2018 4
2019 5
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Li JZ, et al. Among authors: svarovskaia es. JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. JAMA. 2011. PMID: 21467286 Free PMC article. Review.
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification.
Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES. Hedskog C, et al. Among authors: svarovskaia es. Open Forum Infect Dis. 2019 Feb 22;6(3):ofz076. doi: 10.1093/ofid/ofz076. eCollection 2019 Mar. Open Forum Infect Dis. 2019. PMID: 30949527 Free PMC article.
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
Isakov V, Chulanov V, Abdurakhmanov D, Burnevich E, Nurmukhametova E, Kozhevnikova G, Gankina N, Zhuravel S, Romanova S, Hyland RH, Lu S, Svarovskaia ES, McNally J, Brainard DM, Ivashkin V, Morozov V, Bakulin I, Lagging M, Zhdanov K, Weiland O. Isakov V, et al. Among authors: svarovskaia es. Infect Dis (Lond). 2019 Feb;51(2):131-139. doi: 10.1080/23744235.2018.1535186. Epub 2018 Nov 30. Infect Dis (Lond). 2019. PMID: 30499360 Clinical Trial.
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Hezode C, et al. Among authors: svarovskaia es. J Hepatol. 2018 May;68(5):895-903. doi: 10.1016/j.jhep.2017.11.032. Epub 2017 Dec 6. J Hepatol. 2018. PMID: 29221887 Clinical Trial.
54 results